Validation of long-term handling and storage conditions for hematopoietic stem cell products for autologous transplants.

Anfal Mohanna, Amani Owaidah, Ahmed Albahrani, Sara Aldossary, Norah Almulhem, Hani Almohanna
Author Information
  1. Anfal Mohanna: Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
  2. Amani Owaidah: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia.
  3. Ahmed Albahrani: Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
  4. Sara Aldossary: Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
  5. Norah Almulhem: Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
  6. Hani Almohanna: Research Center, King Fahad Specialist Hospital, Dammam, Saudi Arabia.

Abstract

Hematopoietic stem cells (HPSCs) are multipotent stem cells that can differentiate into lymphoid and myeloid progenitors, giving rise to white blood cells (WBCs), red blood cells (RBCs), and platelets. HPSCs are a widely used treatment for many hematological non-malignant and malignant disorders. HPSCs can be used in the fresh or cryopreserved state for future use. Fresh HPSCs are typically stored at 2-6°C for up to 72 hours and are primarily used for allogeneic transplants or autologous transplants in myeloma and lymphoma patients. However, in some cases of autologous donations, HPSC transplantation is delayed more than three days after collection. In such situations, the cells are thawed after short-term preservation, resulting in a 35% cell viability loss. This study aimed to investigate the quality of HPSCs products after long-term storage exceeding 72 hours. The quality of HPSCs products was assessed by measuring viable CD34+ cell count, the total number of nucleated cells (TNC), and HPSCs recovery after different storage intervals of up to 120 hours in hypothermal storage. The mean total cell viability decreased by 2.18% within 72 hours and 7.4% within 120 hours, while mean CD34+ cell recovery was 92.61 % at 72 hours and 83.83 % at 120 hours in hypothermal storage. The mean TNC recovery was 89.93% at 72 hours and 76.18 % at 120 hours. All products were free from bacterial contamination for up to 120 hours under hypothermal storage conditions.

Keywords

References

  1. Leuk Lymphoma. 1993 Aug;10(6):443-51 [PMID: 7691307]
  2. Transfus Apher Sci. 2022 Feb;61(1):103298 [PMID: 34696981]
  3. Arch Med Res. 2003 Nov-Dec;34(6):545-53 [PMID: 14734094]
  4. Cytotherapy. 2021 Jun;23(6):483-487 [PMID: 33678598]
  5. Bone Marrow Transplant. 2002 Jun;29(12):967-72 [PMID: 12098064]
  6. Transfus Med Rev. 2018 Jun 1;: [PMID: 29891441]
  7. Respiration. 2013;85(1):3-10 [PMID: 23257690]
  8. Transfusion. 2022 Oct;62(10):1967-1972 [PMID: 36052689]
  9. Ann Oncol. 2007 Apr;18(4):623-32 [PMID: 17355952]
  10. Bone Marrow Transplant. 2018 Apr;53(4):457-460 [PMID: 29330390]
  11. Hematology Am Soc Hematol Educ Program. 2003;:419-37 [PMID: 14633793]
  12. Sultan Qaboos Univ Med J. 2018 Aug;18(3):e264-e277 [PMID: 30607265]
  13. F1000Res. 2018 Nov 5;7:1746 [PMID: 31489176]
  14. Pol Arch Med Wewn. 2008 Nov;118(11):658-63 [PMID: 19140570]
  15. Coll Antropol. 2010 Mar;34(1):163-9 [PMID: 20432746]
  16. Transfus Apher Sci. 2016 Jun;54(3):324-36 [PMID: 27211042]
  17. Asian J Transfus Sci. 2007 Jul;1(2):71-6 [PMID: 21938237]
  18. Bone Marrow Transplant. 2018 Sep;53(9):1198-1200 [PMID: 29599528]
  19. Transfusion. 2011 Jan;51(1):137-47 [PMID: 20609197]

MeSH Term

Humans
Autografts
Transplantation, Autologous
Hematopoietic Stem Cells
Antigens, CD34
Blood Platelets

Chemicals

Antigens, CD34

Word Cloud

Created with Highcharts 10.0.0hourscellsHPSCsstoragestem72cell120productsusedtransplantsautologousrecoveryhypothermalmean%canbloodviabilityqualitylong-termCD34+totalTNCwithin83conditionshematopoieticHematopoieticmultipotentdifferentiatelymphoidmyeloidprogenitorsgivingrisewhiteWBCsredRBCsplateletswidelytreatmentmanyhematologicalnon-malignantmalignantdisordersfreshcryopreservedstatefutureuseFreshtypicallystored2-6°CprimarilyallogeneicmyelomalymphomapatientsHowevercasesdonationsHPSCtransplantationdelayedthreedayscollectionsituationsthawedshort-termpreservationresulting35%lossstudyaimedinvestigateexceedingassessedmeasuringviablecountnumbernucleateddifferentintervalsdecreased218%74%92618993%7618freebacterialcontaminationValidationhandlingcryopreservationhypothermicvalidation

Similar Articles

Cited By

No available data.